Researchers from the Gwangju Institute of Science and Technology have developed a deep learning model that predicts unexpected drug-drug interactions (DDIs) based on their effects on gene expression.
Artificial intelligence could enhance how tumor samples are analyzed in the lab—significantly improving how doctors determine the best treatment for cancer patients, a study by researchers at the Icahn School of Medicine at Mount Sinai Memorial Sloan Kettering Cancer Center, and other collaborators suggests.
